entertainment -WSS

entertainment

author：hotspot 2025-09-03 09:23:23 - browse：72

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Britney Spears to release memoir, 'The Woman In Me,' later this year

knowledge

WSS

China sends large group of warplanes, navy ships towards Taiwan in forceful display

After half a century, Israel moves to evict squatter from his cave home on the beach

Women's World Cup brings attention to abuse in soccer

Medicare threatens to cut off funding for HCA's Mission hospital

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

Vermont grapples with historic flooding as more rainstorms head for Northeast

leisure time

entertainment

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

EU fines Illumina $475 million over Grail acquisition

Jerome Adams on the need for new antivirals for Covid

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Activists slam private health insurers over coverage restrictions

BioAge raises $170M for combination therapy with Zepbound

Duchenne breakthrough therapy leaves behind pioneering families

France's anti

Wildfire smoke exposes gaps in outdoor worker protections

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

hotspot

How digital tools helped lower hypertension in marginalized patients

Women's World Cup brings attention to abuse in soccer

France's anti

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

After half a century, Israel moves to evict squatter from his cave home on the beach

knowledge

entertainment

Wikipedia

leisure time